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Abstract
Background: Depression Care for People with Lung Cancer is a complex intervention delivered by
specially trained cancer nurses, under the supervision of a psychiatrist. It is given as a supplement
to the usual care for depression, which patients receive from their general practitioner and cancer
service. The third Symptom Management Research Trial in Oncology (SMaRT Oncology-3 Trial)
will test its efficacy when compared to usual care alone.
Design: A two arm parallel group multi-centre randomised controlled trial. 200 patients will be
recruited through established systematic Symptom Monitoring Services, which screen patients for
depression. Patients will have: a diagnosis of lung cancer; an estimated life expectancy of three
months or more and a diagnosis of Major Depressive Disorder. Patients will be randomised to
usual care or usual care plus Depression Care for People with Lung Cancer. Randomisation will be
carried out by telephoning a secure computerised central randomisation system or by using a
secure web interface. The primary outcome measure is average depression severity. This will be
assessed using scores on the 20-item Symptom Hopkins Checklist (SCL-20D), collected every four
weeks over 32 weeks. Secondary outcomes include severity of anxiety, pain and fatigue; self-rated
improvement of depression; quality of life and satisfaction with depression care.
Trial Registration: Current controlled trials ISRCTN75905964
Background
Depression is a major problem in patients with lung can-
cer. A large survey of cancer patients found that those with
lung cancer had the highest rate of psychological distress
[1]. In addition, depression has been reported in one third
of patients with inoperable lung cancer on entry to clinical
Published: 30 September 2009
Trials 2009, 10:92 doi:10.1186/1745-6215-10-92
Received: 8 May 2009
Accepted: 30 September 2009
This article is available from: http://www.trialsjournal.com/content/10/1/92
© 2009 Walker et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2009, 10:92 http://www.trialsjournal.com/content/10/1/92
Page 2 of 6
(page number not for citation purposes)
trials, with persistence of depressive symptoms in half of
these patients [2].
A systematic review of psychosocial interventions for
patients with lung cancer found only three small ran-
domised controlled trials [3]. The interventions tested in
these, and subsequent trials, have reported modest bene-
fits on depressive symptoms, but none have selected
depressed patients or evaluated interventions intended to
treat depression. There is, therefore, very little evidence to
guide the practical management of depression in patients
with lung cancer.
We have developed a complex intervention (Depression
Care for People with Cancer) for depression in cancer
patients with good prognosis. The SMaRT Oncology-1
Trial found that patients who received the intervention
had significantly better outcomes than those who received
usual care alone at three months and that this difference
was sustained at six and twelve months [4]. Whilst these
results are encouraging, they cannot be generalised to
patients with lung cancer, who have a relatively limited
life expectancy and different needs. We, therefore, pro-
pose to evaluate the efficacy of an adapted form of Depres-
sion Care for People with Cancer in patients with lung cancer
(Depression Care for People with Lung Cancer).
Trial hypotheses
Supplementing usual care with Depression Care for People
with Lung Cancer will improve the following over eight
months (32 weeks):
• depressive symptoms
￿ other symptoms (pain, fatigue, anxiety)
￿ functioning
￿ quality of life
￿ satisfaction with depression care
Methods
Design
A two-arm parallel group randomised controlled trial
with outcome data collection every 4 weeks to 32 weeks
post-randomisation.
Patients
200 patients will be recruited from lung cancer outpatient
clinics in NHS Scotland. The majority of patients will be
recruited from cancer clinics in NHS Lothian and NHS
Greater Glasgow and Clyde.
To be included in the trial patients must:
￿ Have a diagnosis of lung cancer.
￿ Be aged 18 or over.
￿ Have a predicted survival, estimated by their cancer spe-
cialist, of three months or more.
￿ Have symptoms which meet DSMIV criteria for Major
Depressive Disorder (MDD), with symptoms of the cur-
rent Major Depressive Episode (MDE) present for four
weeks or more using the inclusive approach to diagnosis
[5].
Patients will be excluded if:
￿ They are unable to provide informed consent to partici-
pate.
￿ The episode of depression is chronic (defined as a his-
tory of continuous depression for at least two years).
￿ They are judged to require urgent psychiatric care.
￿ They are receiving active psychiatric or psychological
treatment from specialist mental health services.
￿ They have cognitive impairment or communication dif-
ficulties (including inability to adequately understand
verbal explanations or written information in English)
which are incompatible with the intervention.
￿ They have known cerebral metastases.
￿ They are unable to participate regularly in treatment ses-
sions.
￿ The intervention is judged to be inappropriate due to a
medical condition which requires alternative treatment.
￿ The intervention is judged to be inappropriate due to a
psychiatric condition which requires alternative treatment
(psychotic illness, bipolar affective disorder, obsessive
compulsive disorder, substance abuse or dependence).
￿ Their participation in the trial is judged to be inappro-
priate on other clinical grounds.
N.B Patients receiving active cancer treatments will not be
excluded unless they fulfil one or more of the exclusion
criteria listed above.
Patient identification and enrolment
In order to obtain a representative sample, the majority of
patients will be identified through the Symptom Monitor-
ing Service (SMS) in outpatient clinics attended by lung
cancer patients. The SMS is part of the routine NHS careTrials 2009, 10:92 http://www.trialsjournal.com/content/10/1/92
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for patients attending these clinics. It comprises two
stages:
Stage 1: Patients complete self-report questionnaires in
the clinic to evaluate their symptoms, including emo-
tional distress (Hospital Anxiety and Depression Scale,
HADS). A summary of each patient's symptoms is gener-
ated for their oncology team.
Stage 2: Patients with high emotional distress scores
(HADS total score of 15 or more) receive a brief tele-
phone-delivered, depression screening interview. When
clinically relevant, a report is generated for the patient's
general practitioner (GP) and oncologist.
The SMS staff will ask patients, with an MDE of at least
four weeks' duration and a cancer prognosis of three
months or more, to give permission for their contact
details to be passed to the research team. It will be made
clear that patients who do so will not be obliged to partic-
ipate in the trial. Clinicians may wish to refer patients to
the trial from other lung cancer clinics. In this instance,
the patient will be referred to Stage 2 of the SMS.
Once patients have given permission, the research team
will provide them with a trial information leaflet (usually
by post) and will contact them directly (usually by tele-
phone). Patients will be informed, during the telephone
call, that if they are interested in taking part, their suitabil-
ity for inclusion in the trial must first be assessed. Infor-
mation will be required from patients' medical records in
order to achieve this.
Patients will therefore be asked, at this stage, to give verbal
consent for the research team to access their medical
records. This will minimise the number of unnecessary
face-to-face assessments. Consent to access medical
records is required as the researchers do not provide the
patient's usual clinical care. The patient's records will be
used to determine the presence or absence of specific
inclusion and exclusion criteria, before they are seen for a
face-to-face assessment (if appropriate). If the patient
does not give consent for the research team to access their
records at this stage, consent will be obtained during the
face-to-face assessment.
At the face-to-face assessment, patients will be given a full
explanation of the two treatment allocations and the pro-
cedures for randomisation and outcome data collection.
Written informed consent will then be obtained from
patients for the eligibility assessment and, if appropriate,
trial participation. Patients will be asked to consent to the
information gathered about them being retained even if
they are ineligible to participate in the trial. This informa-
tion will be used to determine the generalisability of the
trial findings.
The information retained from medical records and the
face-to-face assessment will be used to determine eligibil-
ity. Eligibility assessments will be carried out by trained
research staff (senior nurses and psychiatrists) and will
include administration of the major depression compo-
nent of the Structured Clinical Interview for DSMIV
(SCID) to confirm the patient's diagnosis of major depres-
sion. If the patient is eligible to participate, their willing-
ness to do so will be confirmed before randomisation. The
patient's details will be entered into a database via an
automated telephone service or secure website. The
patient's treatment allocation will be automatically gener-
ated. The research team will inform the patient of their
allocation either face-to-face or by telephone. At all stages
the research team will endeavour to record reasons for
non-participation.
Trial treatment - comparison (usual care)
The patient's GP and oncologist will be informed of their
diagnosis of MDD. Patients will receive the usual clinical
management for their depression. Data will be collected
from all patients to allow a retrospective description of the
'usual care' that they receive.
Trial treatment - intervention (usual care supplemented 
with Depression Care for People with Lung Cancer)
In addition to the usual care described above, patients will
receive a complex intervention, Depression Care for People
with Lung Cancer. The intervention will be delivered by
specially trained Care Managers (cancer nurses) under the
supervision of the SMaRT Psychiatry team. Patients will be
allocated to Care Managers systematically, being allocated
to the next Care Manager on the appropriate site-specific
list. If the allocated Care Manager is unable to see the
patient for their first treatment session within two weeks
(e.g. due to leave or staff sickness), the patient will be allo-
cated to the next listed Care Manager.
The intervention is described in detail in the Depression
Care for People with Lung Cancer Treatment Manual and
comprises two phases:
a) Treatment Phase: patients will be offered a maximum
of ten 30-45 minute sessions with their Care Manager over
a 16 week period (patients are expected to receive an aver-
age of six to eight sessions).
b) Maintenance phase: patients will then receive active
treatment follow-up by telephone every four weeks until
the end of their participation in the trial.
During the Treatment Phase the patient's Care Manager
will: (a) Coordinate their depression care by liaising with
all relevant health professionals; (b) Monitor their symp-
toms of depression, using a brief standardised depression
questionnaire (Patient Health Questionnaire-9, PHQ-9),Trials 2009, 10:92 http://www.trialsjournal.com/content/10/1/92
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at each session; (c) Provide a brief psychological interven-
tion comprising education about depression and its man-
agement (including the use of antidepressant medication,
being active and coping with problems better) and Prob-
lem Solving Treatment. A member of the SMaRT Psychia-
try Team will attend a session, along with the Care
Manager, early in the Treatment Phase, when it is neces-
sary to advise the patient's GP regarding the prescription
of antidepressant medication. Treatment sessions will be
delivered at the cancer clinic, at home, in the hospice.
During the Maintenance Phase patients will be asked to
complete the PHQ-9 at monthly follow-up telephone
calls. Patients' responses to this questionnaire will be
reviewed by their Care Manager and appropriate action
will be taken as necessary.
All patients will be discussed during weekly supervision
sessions, provided by the SMaRT Psychiatry Team. In
addition, a member of the Psychiatry Team will be availa-
ble to respond to emergencies. At any stage of treatment
patients who report suicidal thoughts will be discussed
with the Psychiatry Team and an appropriate manage-
ment plan will be implemented. A supervising psychiatrist
will review all patients who in their opinion: (a) require a
diagnostic re-assessment; (b) have failed to achieve a
treatment response (defined as a 50% drop in their PHQ-
9 score and a PHQ-9 score of <10) by session five or week
eight of the Treatment Phase (whichever is earlier); (c)
require assessment for referral to general adult psychiatric
care (patients with high suicide risk, psychosis or mania
and those requiring inpatient care).
Patients' adherence to the intervention will be monitored
by recording their attendance at treatment sessions, com-
pletion of homework, antidepressant prescription (drug
and dose) and self-reported compliance with medication.
In order to ensure Care Manager's compliance with the
treatment manual all treatment sessions will be video/
audio recorded with the patient's permission.
Recordings and treatment notes will be reviewed regularly
by the SMaRT Psychiatry Team and a randomly selected
10% sample of recordings will be independently reviewed
to assess adherence to the Treatment Manual, rated on a
standardised adherence checklist, designed specifically for
this intervention.
Primary outcome measure
The primary outcome measure is average depression
severity. This will be assessed using SCL-20D scores, col-
lected every four weeks over 32 weeks.
Secondary outcome measures
The following secondary outcome measures are listed
below. These will also be assessed using an average of the
scores collected every four weeks over 32 weeks:
￿ Patients' self-rated improvement of depression, meas-
ured by a five point global improvement scale.
￿ Severity of anxiety symptoms, measured by the SCL-
10A.
￿ Severity of pain and fatigue, measured by the relevant
symptom scales of the EORTC QLQ-C30.
￿ Physical, social and role functioning, and overall health
and quality of life measured by the relevant scales of the
EORTC QLQ-C30.
￿ Patient's satisfaction with depression care, measured by
a 5-point Likert scale item developed specifically for the
trial.
Measures of satisfaction with Depression Care for 
People with Lung Cancer
Assessed at 16 weeks, in patients randomised to usual care
supplemented with Depression Care for People with Lung
Cancer using a semi-structured interview.
Measures of cost and health-related quality of life
The following economic outcome measures will be
assessed at 4, 8, 12, 16, 20, 24, 28 and 32 weeks from ran-
domisation:
￿ Cost of 'usual care' treatments received for depression.
￿ Cost of health care service use (primary, secondary and
community based).
￿ Cost of the trial intervention.
￿ Health related quality of life, measured by EQ-5D.
Data collection
Baseline data will be obtained by the assessor at the end
of the face-to-face assessment as near as possible prior to
randomisation.
Outcome data will be obtained by telephone or by face-
to-face interview by a dedicated team who are blind to
group allocation and are situated and managed independ-
ently from the trial team. This team will be managed by
the Scottish Mental Health Research Network (SMHRN).
Outcome data will be collected at 4, 8, 12, 16, 20, 24, 28
and 32 weeks from randomisation. The date of comple-Trials 2009, 10:92 http://www.trialsjournal.com/content/10/1/92
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tion of all questionnaires will be noted. Data collection
will aim to be within one week either side of the specified
follow-up date. Measures of satisfaction with the trial
intervention will be collected by a researcher separate
from the outcome data collection team.
Data collection instruments
The following data will be collected from patients at base-
line, 4, 8, 12, 16, 20, 24, 28 and 32 weeks:
￿ Symptom Checklist Depression Scale (SCL-20D).
￿ Symptom Checklist Anxiety Scale (SCL-10A).
￿ European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ-
C30).
￿ Patient's satisfaction with depression care (question
developed specifically for the trial).
￿ EuroQol-5D (EQ-5D).
￿ Treatments received for depression (measures devel-
oped specifically for the trial).
￿ Use of health care services (measures developed specifi-
cally for the trial).
At baseline, demographic details and information about
the patient's cancer will also be collected. Satisfaction with
the trial intervention will be assessed at 16 weeks using a
semi-structured interview, developed specifically for the
trial.
Sample size
The sample size of 200 will give 90% power at the 5% sig-
nificance level to detect a standardised difference of 0.46,
that is a mean difference of 46% of the underlying stand-
ard deviation. It is anticipated that this standard deviation
will be of the order of 0.6 to 0.7. The trial will have 80%
power to detect a standardised difference of 0.40.
Method of randomisation
In order to ensure similarity in the baseline characteristics
of the two treatment groups randomisation will be carried
out using a combination of stratification and minimisa-
tion. Stratification will be by trial centre (Edinburgh, Glas-
gow) and minimisation variables will be age (≤60, 61-69,
≥70), lung cancer type (small cell, non-small cell, other)
and sex. The process of stratification and minimisation
will be carried out by a telephone/web-based randomisa-
tion system developed by the Division of Clinical Neuro-
science (DCN) Clinical Trials Unit at the University of
Edinburgh.
Statistical analyses
A single main analysis will be performed at the end of the
trial when all outcome data have been collected. An inde-
pendent Data Monitoring Committee will review confi-
dential interim analyses of accumulating data at least
annually. A detailed Statistical Analysis Plan will be devel-
oped prior to closure of the trial database and prior to the
unblinding of the treatment allocations.
The main analysis will be performed blind to treatment
allocation on the 'intention to treat' principle. With such
an ill patient population it is anticipated that missing val-
ues will be common, either resulting from individual
missed assessments or due to patients dying or deteriorat-
ing to such an extent that they become unable to comply
with assessments. This will be handled in the primary
analysis by using an 'area under the curve' approach to cal-
culate the mean SCL-20D score. The areas will be calcu-
lated using the trapezoidal rule.
Recognising that this is an efficacy trial, a 'per protocol'
analysis will also be performed and reported. Patients will
be excluded from the per protocol analysis if they were
allocated to 'usual care plus Depression Care for People
with Lung Cancer' and received fewer than four treatment
sessions. This criterion will be applied without knowledge
of outcome.
Economic analyses
The economic analyses will examine the cost-effectiveness
of the complex intervention from an NHS perspective.
Resource usage will be collected in the trial in relation to
primary health care, community health and secondary
health care services. These data will be collected from
questionnaires administered to patients at each follow up
point. The questionnaires will be designed for this study
and will be based on questionnaires used in economic
evaluations of other interventions.
Unit cost estimates, from routine published sources such
as PSSRU Unit Costs of Health and Social Care [6], will
then be applied to resource use data collected above to
generate patient level cost estimates which will be pre-
sented as a mean cost with a measure of uncertainty. EQ-
5D data will facilitate estimation of health-related quality
of life, which will be expressed in terms of health states
within the 245-state classification and in terms of health
state values based on the preferences of a sample of the
UK public [7]. Mean utility for each treatment allocation
will be estimated with a measure of uncertainty. The anal-
yses above will enable the estimation of mean differences
in costs and effects for the treatment and control alloca-
tions. These will be presented with 95% confidence inter-
vals around the differences in costs and effects.
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ness acceptability curve (CEAC), a graphical representa-
tion of the probability of an intervention being cost-
effective [8].
Approvals and sponsorship
SMaRT Oncology-3 has been approved, with favourable
assessments at all sites, by the Scotland A Research Ethics
Committee (ref: 08/MRE00/95). Management approval
has been granted by the Research and Development
Offices of NHS Lothian and NHS Greater Glasgow. The
trial is co-sponsored by the University of Edinburgh and
NHS Lothian Health Board.
Timescales
Recruitment commenced January 2009. The target for
recruitment closure is November 2010, with outcome
data collection continuing until July 2011.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JW participated in the design and coordination of the trial
and drafted the manuscript. JC participated in the coordi-
nation of the trial. MS conceived of the trial, participated
in its design and coordination and helped to draft the
manuscript. All authors read and approved the final man-
uscript.
Acknowledgements
Funder: Cancer Research UK. The Funder had no role in study design or 
manuscript writing.
Trial Management: Michael Sharpe, Jim Cassidy, Gordon Murray, David 
Weller, Jane Walker, Christian Hansen, Gerry Richardson, Lucy Wall, Mark 
Sculpher, Stephen Palmer.
Trial Steering Committee: Amanda Ramirez, Graham Dunn, Michael Ben-
nett, Galina Velikova, Gillian McHugh, Simon Gilbody, Alison Richardson, 
Peter Rainey.
Data Monitoring Committee: John Geddes, Ed Juszczak, Dan Stark.
References
1. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S:
The Prevalence of Psychological Distress by Cancer Site.  Psy-
chooncology 2001, 10(1):19-28.
2. Hopwood P, Stephens RJ: Depression in Patients With Lung
Cancer: Prevalence and Risk Factors Derived From Quality-
of-Life Data.  J Clin Oncol 2000, 18(4):893-903.
3. Carlsen K, Jensen AB, Jacobsen E, Krasnik M, Johansen C: Psychoso-
cial Aspects of Lung Cancer.  Lung Cancer 2005, 47(3):293-300.
4. Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, McHugh
G, Walker A, Sharpe M: Management of Depression for People
With Cancer (SMaRT Oncology 1): a Randomised Trial.  Lan-
cet 2008, 372(9632):40-8.
5. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders.  4th edition. Washington DC ed.
American Psychiatric Association; 1994. 
6. Curtis L: Unit costs of health and social care 2007.  Canterbury:
Personal Social Services Unit, University of Kent; 2007. 
7. Dolan P, Gudex C, Kind P, Williams A: A social tariff for EuroQol:
results from a UK general population survey (CHE discus-
sion paper no.138).  York: Centre for Health Economics; 1995. 
8. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the
role of cost-effectiveness acceptability curves.  Health Econ
2001, 10(8):779-87.